Known targets — ChEMBL curated mechanism
ATP1A1ATP1A2ATP1A3ATP1A4ATP1B1ATP1B2ATP1B3FXYD2
The experimentally established mechanism targets of Digitoxin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATP1A1 known ✓ | P05023 | 10/20 | 1.00 |
| ▸ | ATP1B1 known ✓ | P05026 | 10/20 | 1.00 |
| ▸ | ATP1A3 known ✓ | P13637 | 10/20 | 1.00 |
| ▸ | ATP1B2 known ✓ | P14415 | 10/20 | 1.00 |
| ▸ | ATP1A2 known ✓ | P50993 | 10/20 | 1.00 |
| ▸ | ATP1B3 known ✓ | P54709 | 10/20 | 1.00 |
| ▸ | FXYD2 known ✓ | P54710 | 10/20 | 1.00 |
| ▸ | ATP1A4 known ✓ | Q13733 | 10/20 | 1.00 |
| ▸ | TP53 | P04637 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 1.00 |
| ▸ | NPC1 | O15118 | 2/20 | 1.00 |
| ▸ | STAT3 | P40763 | 2/20 | 1.00 |
| ▸ | RAB9A | P51151 | 2/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | SLCO4C1 | Q6ZQN7 | 1/20 | 1.00 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.81 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Digitoxin SCHEMBL17864034 | 1.00 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| Digitoxin SCHEMBL18949488 | 1.00 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| Digitoxin SCHEMBL18947798 | 1.00 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| Digitoxin SCHEMBL2321116 | 1.00 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| Digitoxin SCHEMBL12038722 | 1.00 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| Digitoxin SCHEMBL16442430 | 1.00 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| Digitoxin SCHEMBL17862021 | 1.00 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| Digitoxin SCHEMBL20582729 | 1.00 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| Digitoxin SCHEMBL20970016 | 1.00 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 | |
| Digitoxin SCHEMBL18542099 | 1.00 | ATP1A1 (1.00) | ATP1A1ATP1B1ATP1A3ATP1B2ATP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 17981 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026102542-A1 | ATPASE INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NON-NEUROLOGICAL DISORDERS | HAPLO THERAPEUTICS INC. (CA) | 2026-05-21 | — | — | WO | claimed |
| CN-122055374-A | Lipid compounds and compositions for tissue-specific delivery of active substances | 韩国生命工学研究院 | 2026-05-15 | — | — | CN | claimed |
| CN-122024819-A | Method for screening atopic dermatitis key autophagy genes based on transcriptome and machine learning | 常德市第一人民医院 | 2026-05-12 | — | — | CN | claimed |
| WO-2026087680-A1 | TREATMENT FOR CARDIOVASCULAR DISEASE | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| WO-2026087695-A1 | TREATMENT FOR METABOLIC DISORDER | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| EP-3730131-B1 | TREATMENT OF BRAIN CANCER BY CONTINUOUS INFUSION OF COENZYME Q10 | BPGBIO INC (US) | 2026-04-22 | — | — | EP | claimed |
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| EP-4637824-A1 | METHOD OF PREVENTING AND TREATING ALZHEIMER'S DISEASE AND RELATED DEMENTIAS WITH DRUGS INHIBITING THE INTERACTION BETWEEN 14-3-3G PROTEIN AND HEXOKINASE-1 PROTEIN | BIOVENTURES, LLC (US) | 2025-10-29 | — | — | EP | claimed |
| WO-2025217305-A1 | DEVICES, KITS, AND METHODS FOR DELIVERING MEDICATION VIA THE LUNGS | INCARDA THERAPEUTICS, INC. (US) | 2025-10-16 | — | — | WO | claimed |
| US-20250295693-A1 | HYBRID TUMOR/CANCER THERAPY BASED ON TARGETING THE RESOLUTION OF OR INDUCING TRANSCRIPTION-REPLICATION CONFLICTS (TRCS) | JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG (DE) | 2025-09-25 | — | — | US | claimed |
| US-4182330-A | Means for administering amphipathic medicament | ALZA CORPORATION (US) | 1980-01-08 | — | — | US | claimed |
| US-4133949-A | Dicarboxylic acid esters of cardiac glycosides | BOEHRINGER MANNHEIM GMBH (DE) | 1979-01-09 | — | — | US | claimed |
| US-4115539-A | RADIOIMMUNOASSAY, REACTION PRODUCT WITH ISOCYANATES | UNION CARBIDE CORPORATION (US) | 1978-09-19 | — | — | US | claimed |
| US-4067960-A | GELATIN CAPSULE, CARDIOTONIC | R. P. SCHERER LIMITED (EN) | 1978-01-10 | — | — | US | claimed |
| US-4064227-A | Radioimmunoassay method for the determination of cardiotonic glycosides | MALLINCKRODT, INC. (US) | 1977-12-20 | — | — | US | claimed |
| US-4056608-A | IMMUNOASSAY | SYVA COMPANY (US) | 1977-11-01 | — | — | US | claimed |
| US-4039652-A | ANTIGENS, ANTIBODIES | MILES LABORATORIES, INC. (US) | 1977-08-02 | — | — | US | claimed |
| US-3995019-A | FOR RADIOIMMUNOASSAY CONSISTING OF A SPECIFIC ANTIBODY RADIOLABELED, ANTIGEN, POLYETHYLENE GLYCOL, AND GAMMA GLOBULIN | BAXTER TRAVENOL LABORATORIES, INC. (US) | 1976-11-30 | — | — | US | claimed |
| US-3980764-A | Polymeric competitive protein binding adsorbents for radioassey | CURTIS NUCLEAR CORPORATION (US) | 1976-09-14 | — | — | US | claimed |
| US-3939259-A | GELATIN CAPSULE, ZEIN, SHELLAC, ETHYL CELLULOSE, BEESWAX COATINGS | PESCETTI ANTHONY | 1976-02-17 | — | — | US | claimed |